Prior to Endeavor, Dr. Hood was the co-founder and CEO of Impact Biomedicines, which was acquired by Celgene Corporation for up to $7 billion in 2018. Prior to Impact, he was the co-founder and chief scientific officer of Samumed LLC, a pharmaceutical company focused on advancing regenerative medicine and oncology therapies. Prior to that, Dr. Hood was director of research and co-inventor of fedratinib at TargeGen (subsequently acquired by Sanofi S.A.) where he led a team identifying small molecule kinase inhibitors for the treatment of eye diseases and cancer. He is an inventor on 100+ patents and author on 50+ scientific articles. Dr. Hood obtained a Ph.D. in medical physiology and B.S. in biochemistry from Texas A&M University.